TTYH3 and urinary bladder cancer: The team of Polash Kumar Biswas showed that the expression of TTYH3 was higher in bladder cancer [40] and GC [41] than in normal tissues, which was significantly associated with reduced patient survival, suggesting that TTYH3 may be a therapeutic target.